Researchers from Sweden’s Karolinska Institutet and Japan’s RIKEN Center for Brain Science have pinpointed a pair of brain receptors that regulate the breakdown of amyloid‑beta, the sticky protein that builds up in Alzheimer’s disease. Their work suggests a future where inexpensive, pill‑based medicines could replace today’s costly antibody therapies.
Why amyloid‑beta matters
Alzheimer’s is the most common cause of dementia, and its hallmark is the accumulation of amyloid‑beta plaques in the brain. Under normal conditions, an enzyme called neprilysin helps clear these peptides. Unfortunately, neprilysin activity drops as we age and as the disease progresses.
The role of somatostatin receptors
The team discovered that two somatostatin receptors—SST1 and SST4—work together to keep neprilysin levels healthy in the hippocampus, the memory‑critical region of the brain. When both receptors were genetically removed in mice, neprilysin production fell, amyloid‑beta piled up, and the animals showed noticeable memory deficits.
Activating the receptors shows promise
Researchers then tested a small‑molecule compound designed to turn on SST1 and SST4. In mice engineered to develop Alzheimer‑like pathology, the drug raised neprilysin levels, reduced plaque formation, and improved behavioral performance. Crucially, the treatment did not produce any major side effects.
“We can boost the brain’s own defense against amyloid‑beta simply by stimulating these receptors,” says Per Nilsson, docent at Karolinska Institutet’s Department of Neurobiology.
Potential advantages over antibody therapies
Current leading Alzheimer’s treatments rely on monoclonal antibodies that target amyloid‑beta directly. While effective in some cases, they are extremely expensive and can trigger immune‑related side effects. Small molecules that cross the blood‑brain barrier, like the SST1/SST4 activator, could be manufactured at a fraction of the cost and taken as oral pills, dramatically expanding accessibility.
Both SST1 and SST4 belong to the large family of G‑protein‑coupled receptors, a class of proteins that has yielded many successful drugs because they are well‑understood and easy to target with low‑cost chemistry.